Objectives: Elevated mortality has been observed among individuals with opioid use disorder (OUD) treated in addiction specialty clinics or programs. Information about OUD patients in general healthcare settings is needed in light of the current effort to integrate addiction services into primary healthcare systems. This study examined mortality rates, causes of death, and associated risk factors among patients with OUD in a large general healthcare system. Methods: Mortality data were linked with electronic health records of 2576 OUD patients cared for in a large university health system from 2006 to 2014. Results: There were 465 deaths confirmed (18.1% of the study participants), corresponding to a crude mortality rate of 48.6 per 1000 person-years and standardized mortality ratio of 10. 
O pioid use disorder (OUD) has been identified by the US Department of Health and Human Services as a national public health crisis (Macrae and Hyde, 2015; National Heroin Task Force, 2015) . In the United States, prescription opioid and heroin overdose deaths reached a record high of more than 28,000 in 2014 (CDC, 2016a) . This public health crisis has attracted renewed interest in and attention to better identifying risk factors and implementing strategies that address the recurring opioid epidemic in the United States.
Numerous studies have shown that OUD is associated with elevated morbidity, mortality, and other adverse health and social conditions (Hser et al., 2015) . A systematic review and meta-analysis of 58 cohort studies of opioid-dependent individuals found a pooled all-cause crude mortality rate (CMR) of 20.9 per 1000 person-years and a pooled standardized mortality ratio (SMR) of 14.7, with overdose being the most common cause of death (Degenhardt et al., 2011) . A recent study based on 32,322 OUD patients receiving opioid detoxification and maintenance treatment in publicly funded treatment facilities in California from 2006 to 2010 found a 4-fold increase in mortality risk compared with the general population; this risk increased to 6.1 when individuals were out of methadone maintenance treatment versus 1.8 when they were in methadone maintenance treatment. Further, the single leading cause of death identified by the study was drug or alcohol-related (43.6%).
Traditionally, treatment for OUD in the United States has been provided in specialty addiction treatment clinics such as methadone treatment programs, isolated from the primary healthcare system or general medical settings. Recent healthcare reforms related to the passage of the Federal Mental Health Parity and Addiction Equity Act and Affordable Care Act have offered the opportunity to expand services for substance use disorders (SUDs) in primary care. However, studies have shown that most primary care physicians feel they do not have the education, training, resources, or time to diagnose and treat patients with SUDs (Wakeman et al., 2016) . Recognition of the role of opioid prescribers and the healthcare system in the opioid overdose epidemic has resulted in increased education and training on opioid prescribing practice, but many physicians do not fully appreciate the mortality risks to their patients. Most clinicians are aware of the elevated mortality among OUD patients, particularly heroin users treated in publicly funded SUD treatment systems; however, information on the rates and causes of mortality among OUD patients in the general healthcare system is lacking. The present study is based on hospital and clinic medical records of patients diagnosed with OUD in a large healthcare system. We calculated the mortality rates among these OUD patients by cause and in relation to the general population to investigate risk factors predicting mortality-both by all causes and cause-specific.
METHODS

Sample
We identified 2576 eligible patients aged 18 to 64 years at their first OUD diagnosis (abuse or dependence using International Classification of Diseases [ICD]-9th Edition-CM codes 304.0x, 304.7x, or 305.5x) during an inpatient or outpatient visit from 2006 to 2014 from a university health system electronic health record (EHR) system utilizing Epic software. These medical records contain data on patient demographics and clinical diagnoses.
Mortality data, available through the end of 2014, were obtained from the Centers for Disease Control and Prevention (CDC) National Death Index (NDI). NDI data linkage was performed by CDC staff using probabilistic record linkage methods that utilized patients' Social Security number (SSN), full name, birth date, and sex. Among the 2576 patients, 1683 patients did not have further encounter data beyond the end of 2014 and their death status was determined by the NDI search; the remaining 893 patients were considered alive as their encounter data went beyond the end of 2014. In May 2016, NDI shared date and cause of death (ICD-10th revision) for deaths that occurred as of December 31, 2014. Protocols were approved by the Institutional Review Boards at UCLA and the State of California.
Measures
Causes of death were coded according to the 10th edition of the ICD. Deaths were grouped into the following categories (https://simba.isr.umich.edu/restricted/docs/Mortality/icd_10_ recodes.pdf): drug-related (overdose-both unintentional and intentional, alcohol/drug disorder), cardiovascular disease, cancer, infectious diseases (HIV/AIDS, hepatitis, other infectious disease), liver disease, external causes (suicide, homicide, motor vehicle accident, etc), respiratory disease, and all other causes (see Appendix I, http://links.lww.com/JAM/A55, for details).
Covariates are based on medical records. Sociodemographic variables included: sex, race, age, and health insurance. Clinical variables were defined from diagnoses (ICD-9 codes) for physical health or diseases (eg, cardiovascular disease, cancer, diabetes), SUDs (eg, tobacco, alcohol, cannabis), and psychiatric or mental health condition (eg, bipolar disorder, depressive disorder, anxiety disorder). The lists of ICD-9-CM codes utilized in this study may be obtained upon request from the first author.
Data Analysis
Crude mortality rates were calculated by summing person-years and numbers of deaths by age and sex, and calculating a rate per 1000 person-years. Indirect SMRs were calculated by dividing observed deaths in the cohort by expected deaths based on US population mortality rates (as provided by the CDC, National Vital Statistics System) by year, sex, and age group. Follow-up duration was determined using first OUD diagnosis to death, or December 31, 2014, for those not dead.
Chi-square or t tests were used to compare characteristics between living and deceased patients. Cox regression and competing risks regression models were fitted to identify risk factors for all causes of death and to compare the hazard of death from drug-related, cardiovascular, cancer, liverrelated, and all other causes of death, respectively. All hypotheses were tested using a significance level of a ¼ 0.05. Analyses were conducted using SAS 9.4.
RESULTS
There were 465 confirmed deaths (18.1% of the total sample of 2576) over a mean of 3.7 person-years during the follow-up period. Compared with individuals who remained alive, those who died were older at the first OUD diagnosis (48.4 vs 39.8), fewer were female (31.6% vs 41.7%), more were black (11.2% vs 6.8%), and more had no health insurance and therefore self-paid for their care (87.1% vs 51.3%; see Table 1 ). Deceased patients were also more likely to have been diagnosed with other co-occurring SUDs (particularly involving tobacco, alcohol, cannabis, cocaine) and physical health problems (heart, respiratory, hepatitis C virus [HCV] , liver disease, cancer, diabetes). However, the deceased patients did not have higher rates of any psychiatric disorder. The mean age of these patients at death was 51.0 (SD ¼ 11.0).
Mortality rates for all causes of mortality and selected specific mortality causes are provided in Table 2 . The total of 465 deaths over a mean of 3.7 person-years yielded the allcause CMR of 48.6 per 1000 person-years ( Table 2 ). The most common cause of death was drug-related (92 cases, or 19.8%) including accidental poisoning (78 cases, or 16.8%) or drug overdose, intentional poisoning (1.1%), and alcohol or drug disorder (1.9%; Appendix 1, http://links.lww.com/JAM/A55). The next 2 most common causes were cardiovascular disease (17.4%) and cancer (16.8%), followed by infectious diseases (13.5%, with 12.0% HCV and 0.8% HIV), diseases of the digestive system (12.2%, with 4.9% alcohol-related liver disease), and external causes (6.7%). Cause-specific CMRs are provided in Table 2 , with a drug or substance-related CMR of 9.6 per 1000 person-years.
The overall SMR was 10.3 (95% confidence interval [CI] 9.4-11.3), representing a more than 10-fold higher mortality risk compared with the general population adjusted for sex and age (Table 3) . We also provide CMRs and SMRs by key strata. Males had a higher CMR and lower SMR than females. Black and Hispanic OUD patients showed high mortality rates, but they counted for a very small group. Table 4 presents results on hazard ratios (HRs) of factors associated with all-cause deaths, and adjusted HRs (AHRs) for selected causes of death. For these OUD patients, HCV (HR 1.99, 95% CI 1.62-2.46) and alcohol use disorder (HR 1.27, 95% CI 1.05-1.55) are 2 clinically important indicators of overall mortality risk that were statistically significant. None of the diagnoses examined were predictors of drugrelated deaths. Tobacco use disorder (AHR 2.58, 95% CI 1.60-4.17) was associated with increased risk of cardiovascular death. HCV infection (AHR 2.55, 95% CI 1.52-4.26) was associated with elevated cancer mortality risk. HCV (AHR 1.92, 95% CI 1.03-3.60) and alcohol use disorder (AHR 5.44, 95% CI 2.95-10.05) both increased the liverrelated mortality risk.
DISCUSSION
The present study found extremely high rates of mortality among OUD patients treated in a general medical setting, much higher than those reported among patients treated in a publicly funded SUD treatment system. These study patients had a greater disease burden than those reported in prior literature-they were older when first diagnosed with OUD, and they showed high rates of comorbid physical and mental health disorders. Still, the mortality indicators of CMR of 48.6 and SMR of 10.3 are alarming and may reflect several past and current issues with current health care delivery systems in identifying and addressing OUD problems. First, SUDs are not routinely screened for in primary care, and most primary care physicians have not received adequate training to diagnose and treat OUD. It is likely that patients seen in this health system became progressively sicker, as their OUD problem was not identified until very late in its course and after physical health complications had already ensued. Second, even after their OUD was recognized, these patients may or may not have received a referral for OUD treatment, increasing the likelihood that their addiction was untreated. Particularly, if patients had a serious medical condition such as cancer or end-stage liver disease, their OUD might be viewed as a less pressing problem than their medical condition. Third, oral prescription opioid addiction may be more difficult to identify than heroin addiction if the patient is not spontaneously forthcoming, as there are no physical stigmata like needle tracks or abscesses that readily reveal an injection history.
Based on mortality data provided by the CDC NDI, the present study used ICD-10 codes to identify drug-related deaths. Whereas we cannot specify the type of opioids, it should be noted that some of these overdose deaths may involve fentanyl or carfentanyl mixed with heroin (DEA, 2016) . Fentanyl is a synthetic opioid that is much more potent than heroin, and carfentanyl is a fentanyl-related compound. The strength of these powerful synthetic opioids, often added to heroin, heightens the likelihood of overdose and overdoserelated deaths, even among opioid-tolerant users.
No clinically meaningful predictors were identified for drug-related deaths. Nevertheless, HCV and alcohol use disorder were predictors of all-cause deaths. Although treatment regimens for HCV have vastly improved in recent years, considerable barriers to treatment access remain including expensive cost of the medications and restrictions imposed by most health insurance plans. Given the natural course of HCV infection, 20% to 30% of infected patients will develop cirrhosis within 20 to 30 years after infection. Of patients with HCV-induced liver cirrhosis, approximately 67% to 91% will die due to liver disease and 1% to 8% per year will develop hepatocellular carcinoma (Wirth and Manns, 2016) . OUD patients infected with HCV who drink heavily are likely to develop more severe liver injury, progress to cirrhosis, and have increasing risk for liver cancer and mortality. The study found significant associations between alcohol and liver-related death, tobacco and cardiovascularrelated death, and cannabis and other causes of death. It is well known that both tobacco and alcohol account for high rates of deaths in the general population (1 in 5 for tobacco [USDHHS, 2014] ; 1 in 10 for alcohol [CDC, 2016b] ). There is also a growing literature supporting cannabis use is responsible for an increase in morbidity and mortality due to accidents and injury (The National Academies of Science Engineering Medicine, 2017). However, the rates of these disorders in our sample likely represent substantial underdiagnoses, as assessment for SUD is not routine or standardized in primary care clinics. For example, individuals with SUD typically have tobacco use rates above 60% (Lawrence et al., 2009) , whereas it was only 19.6% in our sample. On the contrary, cannabis use disorder rarely comes to clinical attention unless it causes an exacerbation of psychiatric symptoms. Thus, individuals with more severe cannabis use disorder are likely to be over-represented in this study and may have greater mortality risk than the broader general population estimates have previously captured. The 10.8% rate in this study suggests that a subset of this sample had a very severe problem with cannabis use that could relate to mortality in ways cannabis use usually does not, or that the reports of The standardized mortality ratio (SMR) of the total participants is the ratio between the observed number of deaths in the study population and the number of deaths that would be expected, based on the age and sex-specific rates in the US population in 2013, and the age and sex distribution of the study population. SMRs stratified by age at first diagnosis of OUD, mental disorder diagnosis, other drug diagnosis, and chronic pain are also calculated in this way.
yThe SMR of each sex is the ratio between the observed deaths of that sex in the study population and the number of deaths that would be expected, based on the age and sex-specific rates in the US population in 2013 and the age and sex distribution of the study population.
zThe SMR of each race/ethnicity is the ratio between the observed deaths of that race/ethnicity in the study population and the number of deaths that would be expected, based on the age, sex, and race/ethnicity-specific rates in the US population in 2013, and the age, sex, and race/ethnicity distribution of the study population. cannabis use disorder are surrogate markers for some undiagnosed conditions that are associated with mortality. In any event, these findings indicate that the possible relationship between these SUDs and mortality warrants further research. Consistent with existing literature (Wilper et al., 2009; Nandi et al., 2014; Evans et al., 2015) , this study revealed that a higher proportion of the deceased OUD patients were black and uninsured. This finding highlights the need for additional focus on disparities in addiction care and treatment outcomes.
The present study is based on patients seen in a single health system serving predominantly white patients living in the Los Angeles area of the United States, which may limit the study's generalizability. Our findings are dependent on the extent, accuracy, and validity of the data available in the EHR dataset. For example, because OUD diagnosis information was obtained from diagnoses assigned in an EHR, we were not able to distinguish if prescription or nonprescription opioids were used or the route of administration. Both mislabeling of people who do not actually have OUD and under-recognition of true OUD could dilute the true OUD patients in the sample. Possibly, some of the ICD-9 diagnoses of opioid dependence signifying physiologic dependence that would be expected from prescribed opioid has resulted an increase in the proportion of patients who used opiates for pain and who were therefore medically sicker. On the contrary, routine screening for SUDs is not standardized or mandatory in the health system, leaving room for underdiagnoses and inconsistent documentation of these conditions, particularly in cases of less severe disorders.
CONCLUSIONS
The alarmingly high morbidity and mortality among OUD patients revealed in the present study challenge healthcare systems to find new and innovative ways to expand evidence-based strategies for OUD in a variety of settings. Given the chronic, relapsing nature of OUD, and high medical and psychiatric comorbidity, continued care encompassing screening, early intervention, support, and monitoring is essential. In the United States, healthcare providers outside specialty SUD treatment settings have not traditionally been adequately equipped to identify and address patients' drug addictions. Providing medications, such as buprenorphine, buprenorphine-naloxone, methadone, and naltrexone, in combination with counseling, behavioral therapies, and monitoring are evidence-based strategies to treat OUD; however, the optimal care pathways or implementation of these pharmacotherapies into healthcare setting is currently being studied (Jones et al., 2015; Simpatico, 2015; Lasser et al., 2016) . Indeed, expanding access to medication for addiction treatment and training for medical professionals on opioid medication-prescribing practices are among initiatives recently issued by former President Obama to address the prescription opioid and heroin epidemic (The White House, 2016). It seems likely that earlier intervention could prevent some of the excess morbidity and mortality noted in this report and possibly ultimately conserve scarce healthcare resources. Future research is much needed to better engage the entire spectrum of healthcare services, with the goal of developing and delivering efficient and effective chronic care management approaches and services for OUD.
